Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide-Reference-Cited by-同舟云学术

Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide

Published:2021-03-12 Issue:3 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

McAleenan Alexandra¹,Kelly Claire¹,Spiga Francesca¹,Kernohan Ashleigh²,Cheng Hung-Yuan¹,Dawson Sarah¹³,Schmidt Lena¹,Robinson Tomos²,Brandner Sebastian⁴⁵,Faulkner Claire L⁶,Wragg Christopher⁶,Jefferies Sarah⁷,Howell Amy¹,Vale Luke²,Higgins Julian P T¹³⁸,Kurian Kathreena M¹⁹

Affiliation:

1. Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK

2. Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK

3. NIHR Applied Research Collaboration West (ARC West) ; University Hospitals Bristol and Weston NHS Foundation Trust; Bristol UK

4. Department of Neurodegenerative Disease; UCL Queen Square Institute of Neurology; London UK

5. Division of Neuropathology; The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust; London UK

6. Bristol Genetics Laboratory, Pathology Sciences; Southmead Hospital; Bristol UK

7. Department of Oncology; Addenbrooke's Hospital; Cambridge UK

8. NIHR Bristol Biomedical Research Centre; University Hospitals Bristol and Weston NHS Foundation Trust; Bristol UK

9. Bristol Medical School: Brain Tumour Research Centre, Public Health Sciences; University of Bristol; Bristol UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference317 articles.

1. MGMT promoter methylation status in glioblastoma: a single institutional experience;Almuqate;Laboratory Investigation,2018

2. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. [Erratum appears in Acta Neuropathologica 2013;126(1):159];Bady;Acta Neuropathologica,2012

3. DNA methylation in glioblastoma: impact on gene expression and clinical outcome;Etcheverry;BMC Genomics,2010

4. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. [Erratum appears in Acta Neuropathologica 2013;126(1):159];Bady;Acta Neuropathologica,2012

5. MGMT methylation based outcome prediction is associated with two CpG regions separated by a prediction minimum centred at the initiation start site;Bady;Cancer Research,2012

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway;Journal of Neuro-Oncology;2024-01

2. Neuro-oncology Treatment Strategies for Primary Glial Tumors;Seminars in Neurology;2023-12

3. Predictive value of diffusion MRI-based parametric response mapping for prognosis and treatment response in glioblastoma;Magnetic Resonance Imaging;2023-12

4. Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway;2023-11-21

5. Prognostic prediction models for oropharyngeal squamous cell carcinoma (OPSCC): a protocol for systematic review, critical appraisal and meta-analysis;BMJ Open;2023-10